# Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI

> **NCT04510415** · PHASE1 · TERMINATED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 2 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Olmutinib

## Key facts

- **NCT ID:** NCT04510415
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-29
- **Primary completion:** 2018-12-11
- **Final completion:** 2018-12-11
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study termination by the Sponsor
- **Last updated:** 2020-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04510415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04510415, "Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04510415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*